PubMed:32178765 / 875-1176 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/32178765","sourcedb":"PubMed","sourceid":"32178765","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/32178765","text":"Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis.","tracks":[{"project":"Inflammaging","denotations":[{"id":"T7","span":{"begin":0,"end":301},"obj":"Sentence"},{"id":"T7","span":{"begin":0,"end":301},"obj":"Sentence"}],"attributes":[{"subj":"T7","pred":"source","obj":"Inflammaging"},{"subj":"T7","pred":"source","obj":"Inflammaging"}]},{"project":"yaoziqian_800_3","denotations":[{"id":"T7","span":{"begin":281,"end":300},"obj":"DP"}],"attributes":[{"subj":"T7","pred":"source","obj":"yaoziqian_800_3"}]},{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T8","span":{"begin":281,"end":300},"obj":"DP"}],"attributes":[{"subj":"T8","pred":"source","obj":"Zierdiyeerkenaili_800_3"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Inflammaging","color":"#ecbf93","default":true},{"id":"yaoziqian_800_3","color":"#a593ec"},{"id":"Zierdiyeerkenaili_800_3","color":"#9aec93"}]}]}}